Welcome to Seeking Alpha's Wall Street breakfast, where we cover the top news for investors every morning.

Good morning. Today is Friday, October 20th, and I'm your host Julie Morgan.

CVS pulls a popular drug from its shelves

as legal pressure increases.

Toyota makes an agreement to use Tesla technology

and Jazz Pharmaceuticals is looking at its options.

CVS has decided to pull oral medications that contain the decongestant phenylephrine.

This comes as it and several other leading OTC drug makers and

retailers face a growing number of lawsuits related to the drug's effectiveness.

Thursday the Wall Street Journal reported that CVS was removing products from its shelves

that had phenilephrine as the sole active ingredient. The move comes about a month after an

FDA advisory panel agreed that phenilephrine, which has been on the

market for years, didn't really work when it was taken by mouth. While the FDA is

not bound to the recommendations of its panels, it generally follows them.

The agency has not yet issued a formal decision on whether to allow pills and syrups containing

the popular decongestant to remain on the market.

Nasal sprays containing Fennel-Lefrin do not appear to be an issue.

Meanwhile, a growing number of lawsuits have been filed against drug makers who made the

products and the retailers who sold them.

Last week a law firm in Illinois filed a class action lawsuit specifically aimed at

CVS, alleging that the company misled consumers by manufacturing and marketing a product they should

have known didn't work based on past debates about the drug's effectiveness.

...